InfuSystem Holdings, Inc. (INFU) P/E Ratio History
UndervaluedTrading at 30.4x vs 5Y avg 295.2x · 35th percentile · Below historical baseline · Data 2007–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, InfuSystem Holdings, Inc. (INFU) trades at a price-to-earnings ratio of 30.4x, with a stock price of $9.42 and trailing twelve-month earnings per share of $0.38.
The current P/E is 90% below its 5-year average of 295.2x. Over the past five years, INFU's P/E has ranged from a low of 23.5x to a high of 2597.0x, placing the current valuation at the 35th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, INFU trades at a 37% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, INFU commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our INFU DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
INFU Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
INFU P/E vs Peers
Drug delivery and infusion consumables peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 28.3 | - | +53% | |
| $93M | 18.4 | - | +125% | |
| $2B | 881.5 | - | -84% | |
| $545M | 11.5Lowest | - | +14% | |
| $525M | 78.6 | 5.79Best | +436%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
INFU Historical P/E Data (2007–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $9.23 | $0.38 | 24.6x | -84% |
| FY2025 Q4 | Dec 31 2025 | $8.97 | $0.32 | 28.3x | -81% |
| FY2025 Q3 | - | $10.36 | $0.26 | 39.4x | -74% |
| FY2025 Q2 | Jun 30 2025 | $6.24 | $0.23 | 26.8x | -82% |
| FY2025 Q1 | Mar 31 2025 | $5.38 | $0.14 | 37.6x | -75% |
| FY2024 Q4 | - | $8.45 | $0.10 | 82.1x | -46% |
| FY2024 Q3 | Sep 30 2024 | $6.70 | $0.06 | 105.8x | -31% |
| FY2024 Q2 | Jun 30 2024 | $6.83 | $0.01 | 513.5x | +237% |
| FY2024 Q1 | Mar 31 2024 | $8.57 | $0.00 | 2597.0x | +1604% |
| FY2023 Q4 | Dec 31 2023 | $10.54 | $0.03 | 316.5x | +108% |
| FY2023 Q3 | Sep 30 2023 | $9.64 | $0.04 | 241.0x | +58% |
| FY2023 Q2 | Jun 30 2023 | $9.63 | $0.03 | 321.0x | +111% |
| FY2022 Q3 | Sep 30 2022 | $6.99 | $0.01 | 699.0x | +359% |
| FY2022 Q1 | - | $9.80 | $0.02 | 490.0x | +222% |
| FY2021 Q4 | Dec 31 2021 | $17.03 | $0.07 | 243.3x | +60% |
| FY2021 Q3 | - | $13.03 | $0.54 | 24.1x | -84% |
| FY2021 Q2 | Jun 30 2021 | $20.79 | $0.70 | 29.7x | -81% |
| FY2021 Q1 | Mar 31 2021 | $20.36 | $0.85 | 24.0x | -84% |
| FY2020 Q4 | - | $18.78 | $0.80 | 23.5x | -85% |
| FY2020 Q3 | Sep 30 2020 | $12.82 | $0.35 | 36.7x | -76% |
| FY2020 Q2 | - | $11.54 | $0.26 | 44.6x | -71% |
| FY2020 Q1 | - | $8.49 | $0.09 | 95.4x | -37% |
| FY2019 Q4 | - | $8.53 | $0.06 | 139.8x | -8% |
| FY2019 Q3 | Sep 30 2019 | $5.29 | $0.01 | 766.7x | +403% |
| FY2016 Q3 | Sep 30 2016 | $2.78 | $0.10 | 26.7x | -82% |
| FY2016 Q2 | - | $2.60 | $0.15 | 17.1x | -89% |
| FY2016 Q1 | - | $3.52 | $0.17 | 20.5x | -87% |
| FY2015 Q4 | - | $3.02 | $0.15 | 19.9x | -87% |
| FY2015 Q3 | Sep 30 2015 | $2.76 | $0.11 | 24.8x | -84% |
| FY2015 Q2 | - | $3.19 | $0.10 | 31.5x | -79% |
| FY2015 Q1 | - | $2.71 | $0.11 | 24.3x | -84% |
| FY2014 Q4 | Dec 31 2014 | $3.15 | $0.16 | 19.7x | -87% |
| FY2014 Q3 | - | $3.14 | $0.15 | 21.0x | -86% |
| FY2014 Q2 | Jun 30 2014 | $2.65 | $0.14 | 19.0x | -88% |
| FY2014 Q1 | Mar 31 2014 | $2.78 | $0.10 | 26.7x | -82% |
| FY2013 Q4 | - | $2.14 | $0.08 | 28.0x | -82% |
| FY2013 Q3 | Sep 30 2013 | $1.28 | $0.05 | 27.2x | -82% |
| FY2013 Q2 | Jun 30 2013 | $1.49 | $0.02 | 80.1x | -47% |
| FY2010 Q3 | - | $2.50 | $0.07 | 35.5x | -77% |
| FY2010 Q2 | Jun 30 2010 | $2.55 | $0.04 | 69.7x | -54% |
| FY2010 Q1 | Mar 31 2010 | $2.45 | $0.18 | 13.9x | -91% |
| FY2009 Q4 | - | $2.20 | $0.04 | 59.1x | -61% |
| FY2009 Q3 | Sep 30 2009 | $2.15 | $0.05 | 39.8x | -74% |
| FY2009 Q2 | - | $2.99 | $0.38 | 7.9x | -95% |
| FY2009 Q1 | - | $2.48 | $0.13 | 19.4x | -87% |
| FY2008 Q4 | Dec 31 2008 | $2.35 | $0.56 | 4.2x | -97% |
| FY2008 Q3 | - | $2.35 | $0.80 | 2.9x | -98% |
| FY2008 Q2 | Jun 30 2008 | $3.02 | $0.47 | 6.4x | -96% |
| FY2008 Q1 | Mar 31 2008 | $2.46 | $0.45 | 5.4x | -96% |
| FY2007 Q4 | Dec 31 2007 | $4.15 | $0.24 | 17.1x | -89% |
Average P/E for displayed period: 152.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INFU — Frequently Asked Questions
Quick answers to the most common questions about buying INFU stock.
What is INFU's P/E ratio?
InfuSystem Holdings, Inc. (INFU) trailing twelve-month P/E ratio is 30.4x, based on TTM diluted EPS of $0.38. The 5-year average P/E is 295.2x and the historical range spans 23.5x to 2597.0x.
Is INFU stock overvalued or undervalued?
INFU trades at 30.4x P/E, below its 5-year average of 295.2x. At the 35th percentile of its historical range (23.5x–2597.0x), the stock is priced at a discount to its own history.
Is INFU stock expensive?
No, INFU is not expensive on a historical basis. The current P/E of 30.4x is below the 5-year average of 295.2x and sits at the 35th percentile of its valuation range.
What is INFU's historical P/E range?
Over the past 5 years, INFU's P/E ratio has ranged from 23.5x to 2597.0x, with a median of 82.1x and an average of 295.2x. The current P/E of 30.4x places the stock at the 35th percentile of this range. Full historical data spans 2007–2026.
How does INFU's P/E compare to the S&P 500?
INFU trades at 30.4x P/E versus the S&P 500 median of 24.4x. The 25% premium to the market typically reflects higher expected earnings growth or quality.
How does INFU's valuation compare to Healthcare peers?
InfuSystem Holdings, Inc. P/E of 30.4x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is INFU's PEG ratio?
INFU PEG ratio is N/A, based on a P/E of 30.4x and EPS growth of 181.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is INFU's earnings yield?
INFU earnings yield is 3.29%, the inverse of its 30.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.